Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2005
12/01/2005WO2005113758A1 Process for the production of an influenza vaccine
12/01/2005WO2005113756A1 Method
12/01/2005WO2005113607A2 Measuring degree of polymerisation for capsular saccharides that contain sialic acid
12/01/2005WO2005113603A1 Eradication of helicobacter infection by activation of stomach mast cells
12/01/2005WO2005113602A1 Coiled-coil microbial antigens
12/01/2005WO2005113601A2 Antibodies and molecules derived therefrom that bind to steap-1 proteins
12/01/2005WO2005113589A2 Modified antigen-presenting cells
12/01/2005WO2005113584A1 Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
12/01/2005WO2005113019A2 Methods for the treatment of autoimmune diseases
12/01/2005WO2005113005A2 Transcutaneous and/or transdermal transport of materials
12/01/2005WO2005113003A2 Method for augmenting b cell depletion
12/01/2005WO2005113001A1 Methods of treating cancer using il-21 and monoclonal antibody therapy
12/01/2005WO2005113000A2 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
12/01/2005WO2005112999A2 Cancer treatment with inhibitors of collagen synthesis
12/01/2005WO2005112998A2 Compositions and methods for preventing erythropoietin-associated hypertension
12/01/2005WO2005112997A2 Composition and method for introduction of dna directed or direct rna interference sequence into targeted cells and tissues
12/01/2005WO2005112996A1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives
12/01/2005WO2005112995A1 Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof
12/01/2005WO2005112994A1 Nodavirus-vlp immunization composition
12/01/2005WO2005112993A1 Vaccine for periodontal disease
12/01/2005WO2005112992A1 P. gingivalis vaccine
12/01/2005WO2005112991A2 Vaccines
12/01/2005WO2005112990A2 Treatment of diseases associated with the use of antibiotics
12/01/2005WO2005112894A1 Nucleic acid microspheres, production and delivery thereof
12/01/2005WO2005112893A1 Microspheres comprising protein and showing injectability at high concentrations of said agent
12/01/2005WO2005112892A1 Spray-dried powders containing at least one 1,4 o-linked saccharose derivative and methods for producing the same
12/01/2005WO2005112546A2 Mucinous glycoprotein (muc-1) vaccine
12/01/2005WO2005103081A3 Human monoclonal antibodies against cd20
12/01/2005WO2005099776A9 Steroid sparing agents and methods of using same
12/01/2005WO2005097832A3 Humanized anti-tgf-beta antibodies
12/01/2005WO2005097165A3 Il-28 and il-29 cysteine mutants for treating viral infection
12/01/2005WO2005094391A3 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
12/01/2005WO2005089164A3 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
12/01/2005WO2005082930A3 An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
12/01/2005WO2005082339A3 Medicaments and methods for treating headache
12/01/2005WO2005070967A3 Anti-cancer antibodies with reduced complement fixation
12/01/2005WO2005065015A3 Neutralizing antibodies and methods of use thereof
12/01/2005WO2005062916A3 Methods for generating multimeric molecules
12/01/2005WO2005051330B1 METHOD FOR TREATING HUMAN TUMOR CELLS WITH A NEWCASTLE DISEASE VIRUS STRAIN HAVING A p53 INDEPENDENT ONCOLYTIC EFFECT
12/01/2005WO2005046721A3 Compositions for reducing bacterial carriage and cns invasion and methods of using same
12/01/2005WO2005041868A3 Epidermal growth factor receptor modulation protects normal tissue
12/01/2005WO2005032491A3 Methods and compositions for mycoplasma pneumoniae exotoxins
12/01/2005WO2005027831A3 Modulators of p-selectin glycoprotein ligand 1
12/01/2005WO2005023848A3 Adenoviral epitopes
12/01/2005WO2005011730A8 Microsome vaccine
12/01/2005WO2005005614A3 Combined b-cell and t-cell epitopes on vlp for improved vaccines
12/01/2005WO2004113497A3 Gene delivery to tumors
12/01/2005WO2004094988A3 Tolerance to graft prior to thymic regeneration
12/01/2005WO2004094649A3 Tolerance to graft following thymic reactivation
12/01/2005WO2004092343A3 Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
12/01/2005WO2003049703A8 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
12/01/2005WO2002092012A3 Compositions and methods for treating tumors bearing hmfg and cea antigens
12/01/2005US20050267294 Antibodies with increased affinities for anthrax antigens
12/01/2005US20050267064 Containing unmethylated CpG dinucleotides, and an allergen; desensitization
12/01/2005US20050267057 Redirect a Th2 response to a Th1 response; treating asthma, allergies, infections, cancer immunotherapy; contain unmethylated cytosine-guanine (CpG) dinucleotides
12/01/2005US20050267031 procytotoxic agents for use in treating cancer; antitumor agents; has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group
12/01/2005US20050267028 ligands isolated from Moraxella catarrhalis outer membrane protein which binds to carcinoembryonic antigen cell adhesion molecules (CEACAM) receptors, and inhibits bacterial adhesion to CEACAM expressing cells in vitro; drugs and vaccines used in the treatment or prophylaxis of infections
12/01/2005US20050267025 Compositions and methods for treatment of infectious and inflammatory diseases
12/01/2005US20050267020 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
12/01/2005US20050266550 TC-83-derived alphavirus vectors, particles and methods
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266530 Cynomolgus prostate specific antigen
12/01/2005US20050266506 Method for diagnosing or monitoring carbohydrate metabolism disorders
12/01/2005US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer
12/01/2005US20050266483 Novel method of diagnosing, monitoring, staging, imaging and treating colon cancer
12/01/2005US20050266460 DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
12/01/2005US20050266431 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
12/01/2005US20050266406 Maxs as modifiers of the axin pathway and methods of use
12/01/2005US20050266066 Phospholipid membrane preparation
12/01/2005US20050266030 Outer membrane protein P2 obtained from the strains for use as vaccines; immunogenic effective against a broad range of NTHI bacterial strains
12/01/2005US20050266029 with botulinum toxin
12/01/2005US20050266028 Compositions and methods for modulating an immune response
12/01/2005US20050266027 Live organism product
12/01/2005US20050266026 Multi plasmid system for the production of influenza virus
12/01/2005US20050266025 Novel use
12/01/2005US20050266024 Adjuvant
12/01/2005US20050266023 Generation of virus-like particles and use as panfilovirus vaccine
12/01/2005US20050266022 Methods and compositions for use in the treatment of filovirus mediated disease conditions
12/01/2005US20050266019 Infectious bursal disease virus antigenic isolates and vaccines
12/01/2005US20050266016 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
12/01/2005US20050266015 Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
12/01/2005US20050266014 Tumor antigen based on products of the tumor suppressor gene WT1
12/01/2005US20050266013 Diagnosis of RH factor; using polypeptides to form antibodies; purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens for treating idiopathic thrombocytopenic purpura (ITP) or mistransfusion of Rhesus incompatible blood
12/01/2005US20050266012 Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
12/01/2005US20050266011 Method and formulation for transdermal delivery of immunologically active agents
12/01/2005US20050266010 Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
12/01/2005US20050266008 Human anti-IRTA-5 antibodies
12/01/2005US20050266006 Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
12/01/2005US20050266005 Methods and compositions for treating IL-3 related pathologies
12/01/2005US20050266004 Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
12/01/2005US20050266003 Antibodies and their derivatives that induce apoptosis upon binding to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on activatedT cells; autoimmune diseases, transplant rejection, antiallergens, and T cell-derived cancers, anticarinogenic agents;immunosuppressants; induction of immunological tolerance
12/01/2005US20050266002 Methods for the treatment of cancer using anti-CD40 antibodies
12/01/2005US20050266001 Therapeutic blockade of CD103 interactions to prevent clinical renal allograft rejection
12/01/2005US20050266000 Variable domain library and uses
12/01/2005US20050265999 Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases
12/01/2005US20050265998 Antibody that binds human Toll-like receptor 4 (TLR4)/human MD-2 complex, wherein antibody inhibits 50% of lipopolysaccharide-induced IL-8 production in solution comprising human TLR4/MD-2 transfected HEK293 cells; therapeutic agents to prevent activation of TLRs in autoimmune, inflammatory disorders
12/01/2005US20050265997 Cancer treatment method by inhibiting MAGE gene expression or function
12/01/2005US20050265996 Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
12/01/2005US20050265995 Tissue targeted complement modulators
1 ... 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 ... 1823